Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4854700 | 0.98 | MEN1 (0.33) | MEN1KMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL1024449 | 0.90 | MEN1 (0.31) | MEN1KMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL18983137 | 0.90 | MEN1 (0.31) | MEN1KMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL20974094 | 0.90 | MEN1 (0.31) | MEN1KMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL15910556 | 0.86 | SLC7A5 (0.41) | MAPT | |
| SCHEMBL20679747 | 0.86 | ALDH1A1 (0.41) | ALDH1A1GRIK1 | |
| SCHEMBL15910554 | 0.86 | SLC7A5 (0.41) | MAPT | |
| SCHEMBL203296 | 0.84 | GABRP (0.37) | MEN1KMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL1248340 | 0.84 | GABRP (0.37) | MEN1KMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL18783615 | 0.82 | MEN1 (0.30) | MEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-1697400-B1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AICURIS GMBH & CO KG (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2005118613-A2 | ANTIBACTERIAL AMIDE MACROCYCLES | AICURIS GMBH & CO.KG (DE) | 2005-12-15 | — | — | WO | disclosed |
| US-20050256037-A1 | Antibacterial amide macrocyles | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005033129-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | MEN1 417/4885KMT2A 1095/4885ALDH1A1 277/4885 |
| US-20050256037-A1 | Antibacterial amide macrocyles | AADAC, PAM, NOD2 | MEN1 1754/4885KMT2A 2507/4885ALDH1A1 3883/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | MEN1 417/4885KMT2A 1095/4885ALDH1A1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.